Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Miguel, M. Dimopoulos, E. Stadtmauer, S. Rajkumar, D. Siegel, M. Bravo, Marta Olesnyckyj, R. Knight, J. Zeldis, J. Harousseau, D. Weber (2008)
Longer Duration of Treatment and Maintenance of Best Response with Lenalidomide and Dexamethasone Prolongs Overall Survival in Patients with Relapsed or Refractory Multiple MyelomaBlood, 112
T. Facon, J. Mary, C. Hulin, L. Benboubker, M. Attal, B. Pégourié, M. Renaud, J. Harousseau, G. Guillerm, C. Chaleteix, M. Dib, L. Voillat, H. Maisonneuve, J. Troncy, V. Dorvaux, M. Monconduit, Claude Martin, P. Casassus, J. Jaubert, H. Jardel, C. Doyen, B. Kolb, B. Anglaret, B. Grosbois, I. Yakoub-Agha, C. Mathiot, H. Avet-Loiseau (2007)
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trialThe Lancet, 370
J. Cuzick, S. Erskine, D. Edelman, D. Galton (1987)
A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. A report to the Medical Research Council's working party on leukaemia in adults.British Journal of Cancer, 55
M. Gordon (2006)
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaYearbook of Oncology, 2006
M. Dimopoulos, Christine Chen, A. Spencer, R. Niesvizky, M. Attal, E. Stadtmauer, Maria Petrucci, Zhinuan Yu, Marta Olesnyckyj, J. Zeldis, R. Knight, D. Weber (2009)
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myelomaLeukemia, 23
M. Dimopoulos, R. Orlowski, R. Niesvizky, S. Lonial, N. Brandenburg, D. Weber (2011)
Lenalidomide and dexamethasone (LEN plus DEX) treatment in relapsed/refractory multiple myeloma (RRMM) patients (pts) and risk of second primary malignancies (SPM): Analysis of MM-009/010.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 15_suppl
PG Richardson, P Sonneveld, MW Schuster (2005)
Bortezomib or high-dose dexamethasone for relapsed multiple myelomaN Engl J Med, 352
M. Attal, C. Cristini, G. Marit, D. Caillot, T. Facon, Cyrille Hullin, P. Moreau, C. Mathiot, H. Avet-Loiseau, J. Harousseau, Intergroupe Myelome (2010)
Lenalidomide maintenance after transplantation for myeloma.Journal of Clinical Oncology, 28
J. Miguel, M. Dimopoulos, D. Weber, Marta Olesnyckyj, Zhinuan Yu, J. Zeldis, R. Knight, V. Rajkumar (2007)
Dexamethasone Dose Adjustments Seem To Result in Better Efficacy and Improved Tolerability in Patients with Relapsed/Refractory Multiple Myeloma Who Are Treated with Lenalidomide/Dexamethasone (MM009/010 Sub-Analysis).Blood, 110
M. Dimopoulos, A. Palumbo, M. Attal, M. Beksaç, F. Davies, M. Delforge, H. Einsele, R. Hájek, J. Harousseau, F. Costa, H. Ludwig, U. Mellqvist, G. Morgan, J. San-Miguel, S. Zweegman, P. Sonneveld (2011)
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statementLeukemia, 25
M. Dimopoulos, A. Spencer, M. Attal, H. Prince, J. Harousseau, A. Dmoszyńska, J. Miguel, A. Hellmann, T. Facon, R. Foà, A. Corso, Z. Masliak, Marta Olesnyckyj, Zhinuan Yu, J. Patin, J. Zeldis, R. Knight (2007)
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.The New England journal of medicine, 357 21
H. Brenner, A. Gondos, D. Pulte (2008)
Expected long-term survival of patients diagnosed with multiple myeloma in 2006–2010Haematologica, 94
R. vincent (2008)
Treatment of myeloma: cure vs control.Mayo Clinic proceedings, 83 10
J San Miguel, M Dimopoulos, M Bravo, DM Weber (2009)
Longer duration of treatment and maintenance of best response with lenalidomide + dexamethasone increases overall survival (OS) in patients with relapsed/refractory multiple myeloma (abstract 0949)Haematologica, 94
Robert Kyle, M. Gertz, T. Witzig, J. Lust, M. Lacy, A. Dispenzieri, R. Fonseca, S. Rajkumar, J. Offord, Dirk Larson, Matthew Plevak, Terry Therneau, P. Greipp (2003)
Review of 1027 patients with newly diagnosed multiple myeloma.Mayo Clinic proceedings, 78 1
A. Palumbo, S. Bringhen, S. Zweegman, Giulia Lupparelli, T. Caravita, P. Musto, R. Hájek, A. Spencer, M. Dimopoulos, P. Sonneveld (2011)
Secondary malignancies in elderly myeloma patientsHaematologica, 96
J. Harousseau, M. Dimopoulos, Michael Wang, A. Corso, Christine Chen, M. Attal, A. Spencer, Zhinuan Yu, Marta Olesnyckyj, J. Zeldis, R. Knight, D. Weber (2010)
Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myelomaHaematologica, 95
J. Bladé, D. Samson, D. Reece, J. Apperley, B. Björkstrand, G. Gahrton, M. Gertz, S. Giralt, S. Jagannath, D. Vesole (1998)
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 102
J Blade, D Samson, D Reece (1998)
Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow TransplantBr J Haematol, 102
M. Dimopoulos, M. Hussein, A. Swern, D. Weber (2009)
Full Dose of Lenalidomide for 12 Months Followed by a Lower Maintenance Dose Improves Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma.Blood, 114
Shaji Kumar, S. Rajkumar, A. Dispenzieri, M. Lacy, S. Hayman, F. Buadi, S. Zeldenrust, D. Dingli, S. Russell, J. Lust, P. Greipp, R. Kyle, M. Gertz (2008)
Improved survival in multiple myeloma and the impact of novel therapies.Blood, 111 5
A Phase III randomized , double - blind study of maintenance therapy with lenalidomide ( CC 5013 ) or placebo following autologous stem cell transplantation for multiple myeloma
F. Davies, R. Baz (2010)
Lenalidomide mode of action: linking bench and clinical findings.Blood reviews, 24 Suppl 1
J. Ishak, M. Dimopoulos, D. Weber, R. Knight, A. Shearer, J. Caro (2008)
Declining Rates of Adverse Events and Dose Modifications with Lenalidomide in Combination with DexamethasoneBlood, 112
J. Zeldis, R. Knight, M. Hussein, R. Chopra, G. Muller (2011)
A review of the history, properties, and use of the immunomodulatory compound lenalidomideAnnals of the New York Academy of Sciences, 1222
M. Dimopoulos, E. Terpos (2010)
Lenalidomide: an update on evidence from clinical trials.Blood reviews, 24 Suppl 1
R. Curtis, BrendaK. Edwards, M. Tucker, L. Ries, L. Brown, P. McCarron, D. Freedman, R. Stolzenberg-Solomon, L. Wideroff, D. Albanes, P. Mysliwiec, K. Cronin, A. Schatzkin, N. Caporaso, K. Dodd, B. Hankey, R. Hoover, L. Travis, J. Fraumeni, Robin Wilson, B. Miller, E. Engels (2006)
New malignancies among cancer survivors: SEER Cancer Registries, 1973-2000.
R. Kyle, R. Pierre, E. Bayrd (1970)
Multiple myeloma and acute myelomonocytic leukemia.The New England journal of medicine, 283 21
Jesús Miguel, Vicente Garcia, Javier Batlle, Eduardo Rocha (2009)
Antonio López Borrasca (1926–2008)Haematologica, 94
New Malignanacies Following Hodgkin Lymphoma , Non - Hodgkin Lymphoma , and Myeloma
D. Weber, Christine Chen, R. Niesvizky, Michael Wang, A. Belch, E. Stadtmauer, D. Siegel, I. Borrello, S. Rajkumar, A. Chanan-Khan, S. Lonial, Zhinuan Yu, J. Patin, Marta Olesnyckyj, J. Zeldis, R. Knight (2007)
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.The New England journal of medicine, 357 21
We present the case of a 72-year-old woman diagnosed with multiple myeloma (MM) in 1992 and treated with lenalidomide plus dexamethasone (LD) as third-line therapy. The patient achieved a complete remission (CR) after 6 cycles of LD treatment, was treated with LD for almost 4 years, and has now been in CR for 5 years. This case illustrates the potential of lenalidomide for continuous treatment in MM, with side effects controllable through tailored patient management including step-wise dose adaptations.
memo - Magazine of European Medical Oncology – Springer Journals
Published: Apr 10, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.